Scandion Oncology A/S (SCOL) — Strategic Asset Allocation Index
Scandion Oncology A/S (SCOL) has a Strategic Asset Allocation Index of 3.4% as of June 2023. Strategic assets (PP&E of Skr1.77 Million plus long-term investments of Skr-) total Skr1.77 Million, measured against net assets of Skr52.27 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See Scandion Oncology A/S net asset quality index to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
Scandion Oncology A/S Strategic Asset Allocation Index (2019–2022)
This chart shows how Scandion Oncology A/S's Strategic Asset Allocation Index has evolved across 4 annual periods from 2019 to 2022. As of June 2023, the index stands at 3.4%, representing strategic assets of Skr1.77 Million against net assets of Skr52.27 Million SEK. For live market cap and overall valuation, see Scandion Oncology A/S market capitalisation.
Annual Strategic Asset Allocation Index for Scandion Oncology A/S (2019–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Scandion Oncology A/S from 2019 to 2022, covering 4 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. See Scandion Oncology A/S shareholders equity for net asset value and shareholders' equity analysis.
| Year | SAAI | Strategic Assets (SEK) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 3.2% | Skr2.26 Million | Skr2.26 Million | Skr- | Skr70.33 Million | ▲ +1.7 pp |
| 2021 | 1.5% | Skr1.60 Million | Skr1.60 Million | Skr- | Skr104.54 Million | ▲ +1.2 pp |
| 2020 | 0.3% | Skr448.00K | Skr448.00K | Skr- | Skr155.87 Million | ▼ -0.6 pp |
| 2019 | 0.9% | Skr171.00K | Skr171.00K | Skr- | Skr18.34 Million | — |